Becton Dickinson (BDX) announced that the Conformite Europeenne Marked BD Onclarity HPV Assay for the BD Cor System and the BD Viper LT System have been accepted for the World Health Organization list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low- and middle-income countries.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Starboard takes new stake in Bill Holdings, exits Pfizer position
- Becton Dickinson price target lowered to $202 from $211 at RBC Capital
- Becton Dickinson price target lowered to $210 from $224 at Stifel
- Cautious Outlook for Becton Dickinson Amidst Revenue Growth Challenges and Alaris Product Line Headwinds
- Becton Dickinson price target lowered to $190 from $200 at Piper Sandler